Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gendiag S L focuses its patent prosecution in the Biotechnology & Pharmaceuticals technology area. Currently, the company has 1 pending office action. This workload is assigned to 1 distinct examiner and is situated in the distinct art unit. This distribution points to a specific area of interest within the patent office's classification system. The concentration of all active matters in this way suggests a targeted approach to intellectual property development.
The busiest examiner for the portfolio is COPPINS, JANET L. This individual is responsible for the busiest examiner pending office action. As this represents the total pending volume for the company, the immediate future of the portfolio rests with this examiner's decisions. A practitioner might find that this centralization simplifies the management of the prosecution but also increases the impact of the assigned examiner's specific tendencies. The company's current patent strategy is effectively channeled through this examination path.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16498813 | STATIN FOR PREVENTION/REDUCTION OF ISCHEMIA-RELATED DAMAGE | COPPINS, JANET L | 71d overdue |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16498813 | STATIN FOR PREVENTION/REDUCTION OF ISCHEMIA-RELATED DAMAGE | COPPINS, JANET L | 1628 | §112 | Final Rejection | 71d overdue | Pending | Sep 27, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGendiag S L has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Janet L Coppins has the most, with 1 of Gendiag S L's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
